Personalised medicine and the identification of predictors of the efficacy of specific drugs represent the ultimate goal for the treatment of ulcerative colitis (UC) in order to break the current therapeutic ceiling. JAK inhibitors are a new class of advanced therapies, orally administered, showing a good profile of efficacy and safety in both randomised controlled trials (RCTs) and real-world studies. Unfortunately, to date, it is not possible to draw the ideal profile of a patient maximally benefiting from this class of drugs to guide clinicians' therapeutic choices. Baseline clinical activities and inflammatory biomarkers, as well as their early variation after treatment initiation, emerged as the main predictors of efficacy from post hoc analyses of RCTs with tofacitinib. Similar findings were also observed in the real-life studies including mainly patients with a history of pluri-refractoriness to biological therapies. At last, a few new biomarkers have been explored, even though they have not been validated in large cohorts. This paper provides a review of the current knowledge on clinical variables and biomarkers predicting response to JAK inhibitors in UC.

Cuccia, G., Privitera, G., Di Vincenzo, F., Monastero, L., Parisio, L., Carbone, L., Scaldaferri, F., Pugliese, D., Predictors of Efficacy of Janus Kinase Inhibitors in Patients Affected by Ulcerative Colitis, <<JOURNAL OF CLINICAL MEDICINE>>, 2024; 13 (3): N/A-N/A. [doi:10.3390/jcm13030766] [https://hdl.handle.net/10807/268458]

Predictors of Efficacy of Janus Kinase Inhibitors in Patients Affected by Ulcerative Colitis

Cuccia, Giuseppe;Di Vincenzo, Federica;Carbone, Luigi;Scaldaferri, Franco;Pugliese, Daniela
2024

Abstract

Personalised medicine and the identification of predictors of the efficacy of specific drugs represent the ultimate goal for the treatment of ulcerative colitis (UC) in order to break the current therapeutic ceiling. JAK inhibitors are a new class of advanced therapies, orally administered, showing a good profile of efficacy and safety in both randomised controlled trials (RCTs) and real-world studies. Unfortunately, to date, it is not possible to draw the ideal profile of a patient maximally benefiting from this class of drugs to guide clinicians' therapeutic choices. Baseline clinical activities and inflammatory biomarkers, as well as their early variation after treatment initiation, emerged as the main predictors of efficacy from post hoc analyses of RCTs with tofacitinib. Similar findings were also observed in the real-life studies including mainly patients with a history of pluri-refractoriness to biological therapies. At last, a few new biomarkers have been explored, even though they have not been validated in large cohorts. This paper provides a review of the current knowledge on clinical variables and biomarkers predicting response to JAK inhibitors in UC.
2024
Inglese
Cuccia, G., Privitera, G., Di Vincenzo, F., Monastero, L., Parisio, L., Carbone, L., Scaldaferri, F., Pugliese, D., Predictors of Efficacy of Janus Kinase Inhibitors in Patients Affected by Ulcerative Colitis, <<JOURNAL OF CLINICAL MEDICINE>>, 2024; 13 (3): N/A-N/A. [doi:10.3390/jcm13030766] [https://hdl.handle.net/10807/268458]
File in questo prodotto:
File Dimensione Formato  
jcm-13-00766.pdf

accesso aperto

Tipologia file ?: Versione Editoriale (PDF)
Licenza: Creative commons
Dimensione 609.07 kB
Formato Adobe PDF
609.07 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/268458
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 2
social impact